Female Pattern Hair Loss: Signs, Causes, Diagnosis and Treatment

Female pattern hair loss (FPHL) is the most familiar reason women notice thinner hair over time. It rarely looks like the receding hairline and bald crown that many people picture when they think of balding. Instead it tends to show up slowly, along the part, and it is easy to dismiss for months. This guide covers how it presents, what is known about its causes, how a dermatologist confirms it and what the treatment options look like.

How female pattern hair loss presents

The American Academy of Dermatology (AAD) lists a few early signs. The part gets wider, hair near the temples may recede, and a ponytail can feel thinner than it used to. Without treatment some women go on to develop widespread thinning, although women typically do not lose all their hair.

DermNet describes the condition as diffuse thinning of scalp hair, caused by increased shedding, reduced hair volume or both. A review in the International Journal of Endocrinology and Metabolism adds that it most often affects the top of the head and the upper sides, and that the frontal hairline is usually preserved. That preserved hairline is one of the main visual differences from male pattern hair loss.

Recognised patterns

The same review describes three patterns seen in women:

Ludwig type: diffuse thinning over the crown with the front hairline kept intact.
Christmas tree pattern: thinning that widens toward the front of the central part, producing a triangular shape.
Hamilton type: recession at both temples, closer to the male distribution.

The Sinclair stages

Cleveland Clinic outlines a five-stage scale that clinicians use to describe severity:

Stage	What it looks like
1	Little or no hair loss
2	A slight gap at the center part
3	A wider center part, with thinning on either side
4	Bald spots toward the front of the hairline
5	Advanced hair loss

Older woman with silver hair brushing it back while seated in a sunlit room — Female pattern hair loss is more common after menopause. Photo: Polina Tankilevitch / Pexels

Who gets it and when

The AAD notes that FPHL usually begins in midlife, in the 40s to 60s, though it can start earlier. Cleveland Clinic says it can begin in the 20s or 30s and that risk rises with age, with about one-third of women developing it at some point. Both sources describe it as more common after menopause.

What causes it

Genetics

Heredity plays a strong role. The AAD says the tendency can come from either or both parents, and Cleveland Clinic notes that risk is higher when first-degree relatives have hair loss. DermNet describes the inheritance as polygenic and states that genetic testing for balding risk is not currently recommended because it is unreliable.

Hormones

Hormones are part of the picture, though the details are less clear than in men. Cleveland Clinic explains that dihydrotestosterone (DHT), an androgen, is thought to shrink hair follicles. DermNet points out that most women with FPHL have normal blood androgen levels and that the role of oestrogen is also uncertain. A smaller group of women do have raised androgens, often with acne, irregular periods or excess facial and body hair, which can point to polycystic ovary syndrome (PCOS). FPHL is also known as androgenetic alopecia.

Clinician holding a tablet that shows a magnified image of skin next to a seated patient — Dermoscopy, also called trichoscopy, gives a magnified view of the scalp. Photo: Gustavo Fring / Pexels

How it is diagnosed

The AAD recommends seeing a dermatologist because several other conditions can look similar and need different treatment. In most cases the diagnosis is clinical. Cleveland Clinic describes a scalp exam, a medical history and measurement of the center part and thinning areas.

Tests a dermatologist may use

Dermoscopy (trichoscopy): a magnified view of the scalp. The 2013 review notes that variation in hair shaft diameter affecting at least 20% of hairs is a feature of FPHL.
Hair pull test: gently pulling a small group of hairs. A positive result across the whole scalp suggests that telogen effluvium, a shedding condition, is also present.
Blood tests: DermNet lists sex hormone levels and thyroid function. The review adds ferritin and vitamin D to rule out factors that worsen shedding, and suggests checking for PCOS in women with irregular periods or signs of excess androgens.
Scalp biopsy: DermNet and Cleveland Clinic both list it as an option when the diagnosis is uncertain.

Conditions that can look similar

The review names chronic telogen effluvium, alopecia areata incognito and frontal fibrosing alopecia among the main conditions to rule out. Chronic telogen effluvium causes increased shedding without the follicle shrinking seen in FPHL and does not progress to baldness. Frontal fibrosing alopecia is a scarring condition that pushes the hairline back and can affect the eyebrows.

Dropper tip placed on the parting of red hair to apply a liquid to the scalp — Topical minoxidil is the option the AAD recommends most. Photo: Beyzanur K. / Pexels

Treatment options

DermNet states that there is no cure. Treatment aims to slow or stop progression, and some women regrow hair. The AAD adds that treatment works best when started at the first sign of thinning and that results are lost if treatment stops.

Topical minoxidil

The AAD calls topical minoxidil the most recommended option. It is available without a prescription and is FDA-approved for women in 2% and 5% strengths. Results take 6 to 12 months of daily or twice-daily use, and early shedding can happen when treatment starts. Scalp irritation is a common side effect, and women who are pregnant or breastfeeding should avoid it. DermNet notes that the stronger solution is more likely to cause irritation and unwanted hair growth on the face. The 2013 review reports that a 5% foam used once daily was as effective as the 2% solution used twice daily in one trial.

Prescription tablets

The AAD lists spironolactone, finasteride, flutamide and dutasteride as tablets that may help, while noting that none are FDA-approved for this condition. These drugs can cause birth defects, so they are not appropriate during pregnancy, and dermatologists recommend birth control for premenopausal women who take them. The NHS states plainly that women should not use finasteride, and the 2013 review reports that a controlled study of 1 mg finasteride in postmenopausal women showed no benefit. The same review describes spironolactone as an off-label antiandrogen and concludes that the evidence does not yet support routine antiandrogen use. DermNet adds that low-dose oral minoxidil combined with spironolactone has shown improved hair growth and density.

Procedures and cosmetic options

Option	What the sources say
Hair transplant	May suit some women, depending on whether there is enough healthy donor hair (AAD)
Platelet-rich plasma	Under investigation (DermNet); limited evidence (AAD)
Low-level laser therapy	Benefit unproven, though one device has FDA marketing approval (DermNet)
Camouflage	Coloured sprays, hair-bulking powders and wigs (DermNet)

DermNet advises continuing any treatment for at least six months before judging whether it works, and notes that long-term use is usually needed.

Effects beyond the scalp

DermNet links hair loss with psychological distress, including low self-esteem and depression, and Cleveland Clinic suggests a mental health professional may help when it affects emotional wellbeing. The 2013 review also notes an association between FPHL and metabolic syndrome, and recommends that doctors look at overall health as part of the assessment.